INVENTIVA SOCIEDAD ANÓNIMA (IVA)

During the first quarter, Iovance posted a 45% increase in revenue to $71.4 million, which came in below Wall Street’s estimates of $75.6 million, according to Fiscal.ai data.

Iovance Biotherapeutics reports a 45 percent revenue surge in Q1 2026, driven by Amtagvi sales as analysts adjust price targets for the biotech firm.

On May 7, 2026, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported Q1 EPS of (19c), versus the consensus estimate of (15c). Revenue totaled $71.43M, versus the consensus estimate of $75.66M.

Stock move puts Iovance Biotherapeutics (IOVA) back in focus Iovance Biotherapeutics (IOVA) has drawn attention after recent trading, with the stock closing at $4.11 and posting double-digit total returns over the past month and the past three months. See our latest analysis for Iovance ...

Iovance Biotherapeutics recently received FDA clearance for its IND application to begin a Phase 1/2 trial of IOV-5001, a next-generation IL-12 tethered tumor infiltrating lymphocyte therapy for advanced solid tumors including colorectal and certain breast cancers.